Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

Survey: Physicians need more information to assess impact of NSCLC treatment sequencing

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC).

26 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a clinical-stage rare disease and oncology company focused on sourcing and developing innovative treatments for underserved patient populations, announced today that the companies have entered into a global clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene's investigational RAF dimer inhibitor, lifirafenib and SpringWorks Therapeutics' investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors.

6 Sep 2018

New combination approach may help crush resistance to treatment in lung cancer patients

New-generation lung cancer drugs have been effective in a large number of patients, but within about a year, the patients tend to develop resistance to the therapy.

26 Jul 2018

Inflection Biosciences' dual mechanism inhibitor shows promise as treatment for CLL

Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced the publication of preclinical data showing the company's dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise as a treatment for chronic lymphocytic leukemia.

17 Jul 2018

Researchers use x-ray crystallography to reveal how curcumin inhibits cancer

Through x-ray crystallography and kinase-inhibitor specificity profiling, University of California San Diego School of Medicine researchers, in collaboration with researchers at Peking University and Zhejiang University, reveal that curcumin, a natural occurring chemical compound found in the spice turmeric, binds to the kinase enzyme dual-specificity tyrosine-regulated kinase 2 at the atomic level.

10 Jul 2018

Ocular Therapeutix resubmits NDA for DEXTENZA

Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.

30 Jun 2018

Coffee and the heart – four strong cups a day is beneficial finds study

According to a new study four cups of strong coffee might be the amount that would keep the hearts of older adults healthy. The latest study titled, “CDKN1B/p27 is localized in mitochondria and improves respiration-dependent processes in the cardiovascular system—New mode of action for caffeine,” was published on 21st of June 2018 in the journal PLOS Biology.

25 Jun 2018

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines

Spending on cancer drugs in the United States has nearly doubled in the past five years and continues to grow, imposing substantial financial burden on patients with cancer.

18 Apr 2018

Researchers use innovative method to screen kinases for cancer drug's effectiveness

In recent years, a powerful suite of drugs known as kinase inhibitors have been developed to treat cancer and other diseases. Primary targets of such drugs include a family of receptor tyrosine kinases (RTKs) which protrude from cell surfaces like antennae and can activate cancer-related pathways in virtually all types of cancer when signaling molecules bind with them.

5 Feb 2018

Scientists synthesize new multifunctional compound that has anti-tumor properties

A research team of the UNN Faculty of Chemistry led by Professor Alexei Fedorov has developed and synthesized a new multifunctional compound that possesses anti-tumor properties that are due to several independent effects.

2 Feb 2018

Leading medical societies update molecular testing guideline for lung cancer

Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide.

24 Jan 2018

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna® (nilotinib) US product label.

26 Dec 2017

Overcoming Challenges of Assays of Complex Cellular Models with Real-Time Live-Cell Analysis

There's a continued drive towards making in vitro assays ever more translational towards in vivo models and ultimately the clinic. This ties in with the resurgence of phenotypic screening and is a response to the perceived poor translation of the traditional simple cell-based assays, often developed to study just single protein targets.

From Sartorius 5 Dec 2017

New targeted treatment could benefit patients with certain pancreatic tumors

Researchers at the University of Cincinnati College of Medicine have shown that a new targeted treatment could benefit patients with certain pancreatic tumors by preventing spread of the cancer and protecting their heart from damage--a direct result of the tumor.

1 Dec 2017

Osimertinib provides progression-free survival benefit to Asian patients with EGFR-mutated NSCLC

Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine.

20 Nov 2017

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).

17 Nov 2017

Kinase Inhibitor News and Research

Further Reading

Survey: Physicians need more information to assess impact of NSCLC treatment sequencing

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

New combination approach may help crush resistance to treatment in lung cancer patients

Inflection Biosciences' dual mechanism inhibitor shows promise as treatment for CLL

Researchers use x-ray crystallography to reveal how curcumin inhibits cancer

Ocular Therapeutix resubmits NDA for DEXTENZA

Coffee and the heart – four strong cups a day is beneficial finds study

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines

Researchers use innovative method to screen kinases for cancer drug's effectiveness

Scientists synthesize new multifunctional compound that has anti-tumor properties

Leading medical societies update molecular testing guideline for lung cancer

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Overcoming Challenges of Assays of Complex Cellular Models with Real-Time Live-Cell Analysis

New targeted treatment could benefit patients with certain pancreatic tumors

Osimertinib provides progression-free survival benefit to Asian patients with EGFR-mutated NSCLC

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

Breaking Barriers: ANDYSMANCLUB's Fight for Men's Mental Health on World Mental Health Day

Arrayed CRISPR Screening for Revolutionizing Target Discovery

Innovations in baculovirus–insect cell expression systems

Latest Life Science News